

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
DI-5373 CON N2

In Re Application: Naggi et al.



Serial No.

10/824,549

Filing Date

April 14, 2004

Examiner

Unknown

Group Art Unit

Unknown

PERITONEAL DIALYSIS SOLUTION CONTAINING MODIFIED ICODEXTRINS**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on 6/21/2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Renee Street

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: June 21, 2004

Robert M. Barrett (30,142)
ATTORNEYS FOR APPLICANTS
Bell, Boyd & Lloyd LLC
P.O. Box 1135
Chicago, Illinois 60690-1135

CC:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
DI-5373 CON N2

In Re Application Of: **Naggi et al.**

Serial No.
10/824,549

Filing Date
April 14, 2004

Examiner
Unknown

Group Art Unit
Unknown

Title:

PERITONEAL DIALYSIS SOLUTION CONTAINING MODIFIED ICODEXTRINS

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Naggi et al.
Appl. No.: 10/824,549
Conf. No.: Unknown
Filed: April 14, 2004
Title: "PERITONEAL DIALYSIS SOLUTION CONTAINING MODIFIED ICOD EXTRINS"
Art Unit: Unknown
Examiner: Unknown
Docket No.: DI-5373 CON N2

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, be made during the course of examination of the above-identified application for United States patent. Pursuant to the Official Gazette Notice dated August 5, 2003, copies of the cited U.S. patents and patent applications are not included as this application was filed after June 30, 2003. However, copies of all other cited references can be found in the priority application nos. 09/206,063, filed on December 4, 1998, and 09/882,187, filed on June 15, 2001, or are included with this form.

U.S. PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Inventor</u>
3,878,664	April 22, 1975	Zinke
3,974,034	August 10, 1976	Horn and Kimball
3,978,212	August 31, 1976	Barna
3,993,751	November 23, 1976	Zinke
4,339,433	July 13, 1982	Kartinos et al.
4,489,535	December 25, 1984	Veltman
4,604,379	August 5, 1986	Twardowski and Nolph
4,663,289	May 5, 1987	Veech
4,668,400	May 26, 1987	Veech
4,756,838	July 12, 1988	Veltman
4,761,237	August 2, 1988	Alexander and Myers
4,770,879	September 13, 1988	Okamoto et al
4,879,280	November 7, 1989	Seyffart et al.
4,880,629	November 14, 1989	Okamoto, et al.
4,886,789	December 12, 1989	Milner
4,906,616	March 6, 1990	Gilchrist and Manson
4,959,175	September 25, 1990	Yatzidis
4,976,683	December 11, 1990	Gauthier and Levinson
5,011,826	April 30, 1991	Steudle and Volker
5,039,609	August 13, 1991	Klein
5,122,516	June 16, 1992	Wantanabe et al.
5,436,232	July 25, 1995	Forster, et al.

5,536,469	July 16, 1996	Jonsson, et al.
5,616,248	April 1, 1997	Schal
5,779,357	July 14, 1998	Jonsson and Jonsson
5,780,438	July 14, 1998	Gilchrist and Manson
5,833,949	November 10, 1998	Jonsson and Jonsson
5,869,444	February 9, 1999	Klein
5,945,129	August 31, 1999	Knerr and Wild
6,039,719	March 21, 2000	Wieslander and Cappelli
6,077,836	June 20, 2000	Milner; Jeremiah
6,083,935	July 4, 2000	Wu, et al.
6,214,802	April 10, 2001	Nakamura, et al.
6,241,943	June 5, 2001	Wieslander, et al.
6,248,726	June 19, 2001	Alsop, et al.
6,251,437	June 26, 2001	Fischbach
6,284,140	September 4, 2001	Sommermeier and Passlick-Deetjen
6,306,836	October 23, 2001	Martis et al.
6,429,294	August 6, 2002	Masuda and Yamamoto
6,492,336	December 10, 2002	Mahiot; Arezki
6,663,829	December 16, 2003	Kjellstrand
20020077579A1	June 20, 2002	Tobe
20020144946A1	October 10, 2002	Drauz et al.
20020187940A1	December 12, 2002	Masuda & Hidetoshi
20030044513A1	March 6, 2003	Shah et al.
20030202958A1	October 30, 2003	Strickland and Simon

FOREIGN PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Country</u>
0 022 922B1	May 11, 1983	Europe
0 076 355A3	May 25, 1983	Europe
0 086 553B1	April 1, 1987	Europe
0 115 911B2	October 27, 1993	Europe
0 153 164B1	May 2, 1990	Europe
0 170 275B1	December 27, 1989	Europe
0 207 676B1	June 1, 1994	Europe
0 209 607B1	December 20, 1989	Europe
0 218 900B1	January 22, 1992	Europe
0 347 714A3	December 27, 1990	Europe
0 399 918B1	October 11, 1995	Europe
0 481 257B1	December 6, 1995	Europe
0 593 590B1	November 29, 1995	Europe
0 602 014B1	December 29, 1997	Europe
0 612 528A1	August 31, 1994	Europe
1 354 607A1	October 22, 2003	Europe
2304026A2	December 17, 1990	Japan
2722131B2	March 4, 1998	Japan
09087182A2	March 31, 1997	Japan
2000037452A2	February 8, 2000	Japan
2000245826A2	September 12, 2000	Japan
2002282354A2	October 2, 2002	Japan
2002308782A2	October 23, 2002	Japan
56164113A2	December 17, 1981	Japan
57056422A2	April 5, 1982	Japan
60166378A2	August 29, 1985	Japan

63052009B4	October 17, 1988	Japan
07252137A2	October 3, 1995	Japan
08169836A2	July 2, 1996	Japan
97/06810A1	February 27, 1997	WIPO
99/20249A1	April 29, 1999	WIPO
01/26649A1	April 19, 2001	WIPO
02/081005A3	October 17, 2002	WIPO
03/013553A1	February 20, 2003	WIPO

OTHER DOCUMENTS

Mistry et al., *A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis*, Kidney Int., August 1994, 46(2) pp. 496-503.

Peers et al., *Icodextrin: overview of clinical experience*, Perit. Dial. Int., Jan.-Feb. 1997, 17(1) pp. 22-26.

Posthuma et al., *Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance*, Nephrol. Dial. Transplant, Mar. 1997, 12(3) pp. 550-3.

Peers et al., *Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume*, Artif. Organs, January 1998, 22(1) pp. 8-12.

Krediet et al., *Icodextrin's effects on peritoneal transport*, Perit. Dial. Int., Jan.-Feb. 1997, 17(1) pp. 35-41.

Posthuma et al., *Icodextrin use in CCPD patients during peritonitis: ultrafiltration and serum disaccharide concentrations*, Nephrol. Dial. Transplant, Sep. 1998, 13(9) pp. 2341-4.


Solomons, Organic Chemistry, 2nd Edition, John Wiley and Sons, New York, p. 890 (1976), pp. 652-3, 890.

Eliasson, ed. Carbohydrates in Food, Chapter 4: "Cell Wall Polysaccharide: Structural, Chemical and Analytical Aspects," Marcel Dekker, Inc., New York, (1996) pp 191, 195.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY 

Robert M. Barrett
Reg. No. 30,142
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (312) 807-4204

Dated: June 21, 2004



**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)

PTO Form 1449

Atty Docket No.
DI-5373 CON N2

Application No.
10/824,549

Applicant
Naggi et al.

Filing Date
April 14, 2004

Group
Unknown

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
	3,878,664	April 22, 1975	Zinke			
	3,974,034	August 10, 1976	Horn and Kimball			
	3,978,212	August 31, 1976	Barna			
	3,993,751	November 23, 1976	Zinke			
	4,339,433	July 13, 1982	Kartinos et al.			
	4,489,535	December 25, 1984	Veltman			
	4,604,379	August 5, 1986	Twardowski and Nolph			
	4,663,289	May 5, 1987	Veech			
	4,668,400	May 26, 1987	Veech			
	4,756,838	July 12, 1988	Veltman			
	4,761,237	August 2, 1988	Alexander and Myers			
	4,770,879	September 13, 1988	Okamoto et al			
	4,879,280	November 7, 1989	Seyffart et al.			
	4,880,629	November 14, 1989	Okamoto, et al.			
	4,886,789	December 12, 1989	Milner			
	4,906,616	March 6, 1990	Gilchrist and Manson			
	4,959,175	September 25, 1990	Yatzidis			
	4,976,683	December 11, 1990	Gauthier and Levinson			
	5,011,826	April 30, 1991	Steudle and Volker			
	5,039,609	August 13, 1991	Klein			
	5,122,516	June 16, 1992	Wantanabe et al.			
	5,436,232	July 25, 1995	Forster, et al.			
	5,536,469	July 16, 1996	Jonsson, et al.			
	5,616,248	April 1, 1997	Schal			
	5,779,357	July 14, 1998	Jonsson and Jonsson			
	5,780,438	July 14, 1998	Gilchrist and Manson			
	5,833,949	November 10, 1998	Jonsson and Jonsson			
	5,869,444	February 9, 1999	Klein			
	5,945,129	August 31, 1999	Knerr and Wild			
	6,039,719	March 21, 2000	Wieslander and Cappelli			
	6,077,836	June 20, 2000	Milner; Jeremiah			
	6,083,935	July 4, 2000	Wu, et al.			
	6,214,802	April 10, 2001	Nakamura, et al.			
	6,241,943	June 5, 2001	Wieslander, et al.			
	6,248,726	June 19, 2001	Alsop, et al.			
	6,251,437	June 26, 2001	Fischbach			
	6,284,140	September 4, 2001	Sommermeyer and Passlick-			

Examiner:

Date Considered:

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) PTO Form 1449	Atty Docket No. DI-5373 CON N2	Application No. 10/824,549
	Applicant Naggi et al.	
	Filing Date April 14, 2004	Group Unknown

U.S. PATENT DOCUMENTS							
Examiner's Initials		Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
				Deetjen			
		6,306,836	October 23, 2001	Martis et al.			
		6,429,294	August 6, 2002	Masuda and Yamamoto			
		6,492,336	December 10, 2002	Mahiot; Arezki			
		6,663,829	December 16, 2003	Kjellstrand			
		20020077579A1	June 20, 2002	Tobe			
		20020144946A1	October 10, 2002	Drauz et al.			
		20020187940A1	December 12, 2002	Masuda & Hidetoshi			
		20030044513A1	March 6, 2003	Shah et al.			
		20030202958A1	October 30, 2003	Strickland and Simon			

FOREIGN PATENT DOCUMENTS								
Examiner's Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
		0 022 922B1	May 11, 1983	Europe				
		0 076 355A3	May 25, 1983	Europe				
		0 086 553B1	April 1, 1987	Europe				
		0 115 911B2	October 27, 1993	Europe				
		0 153 164B1	May 2, 1990	Europe				
		0 170 275B1	December 27, 1989	Europe				
		0 207 676B1	June 1, 1994	Europe				
		0 209 607B1	December 20, 1989	Europe				
		0 218 900B1	January 22, 1992	Europe				
		0 347 714A3	December 27, 1990	Europe				
		0 399 918B1	October 11, 1995	Europe				
		0 481 257B1	December 6, 1995	Europe				
		0 593 590B1	November 29, 1995	Europe				
		0 602 014B1	December 29, 1997	Europe				
		0 612 528A1	August 31, 1994	Europe				
		1 354 607A1	October 22, 2003	Europe				
		2304026A2	December 17, 1990	Japan				
		2722131B2	March 4, 1998	Japan				
		09087182A2	March 31, 1997	Japan				
		2000037452A2	February 8, 2000	Japan				
		2000245826A2	September 12, 2000	Japan				
		2002282354A2	October 2, 2002	Japan				
		2002308782A2	October 23, 2002	Japan				

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) PTO Form 1449	Atty Docket No. DI-5373 CON N2	Application No. 10/824,549
	Applicant Naggi et al.	
	Filing Date April 14, 2004	Group Unknown

FOREIGN PATENT DOCUMENTS								
Examiner's Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
		56164113A2	December 17, 1981	Japan				
		57056422A2	April 5, 1982	Japan				
		60166378A2	August 29, 1985	Japan				
		63052009B4	October 17, 1988	Japan				
		07252137A2	October 3, 1995	Japan				
		08169836A2	July 2, 1996	Japan				
		97/06810A1	February 27, 1997	WIPO				
		99/20249A1	April 29, 1999	WIPO				
		01/26649A1	April 19, 2001	WIPO				
		02/081005A3	October 17, 2002	WIPO				
		03/013553A1	February 20, 2003	WIPO				

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Mistry et al., <i>A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis</i> , Kidney Int., August 1994, 46(2) pp. 496-503.
	Peers et al., <i>Icodextrin: overview of clinical experience</i> , Perit. Dial. Int., Jan.-Feb. 1997, 17(1) pp. 22-26.
	Posthuma et al., <i>Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance</i> , Nephrol. Dial. Transplant, Mar. 1997, 12(3) pp. 550-3.
	Peers et al., <i>Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume</i> , Artif. Organs, January 1998, 22(1) pp. 8-12.
	Krediet et al., <i>Icodextrin's effects on peritoneal transport</i> , Perit. Dial. Int., Jan.-Feb. 1997, 17(1) pp. 35-41.
	Posthuma et al., <i>Icodextrin use in CCPD patients during peritonitis: ultrafiltration and serum disaccharide concentrations</i> , Nephrol. Dial. Transplant, Sep. 1998, 13(9) pp. 2341-4.
	Solomons, <i>Organic Chemistry</i> , 2 nd Edition, John Wiley and Sons, New York, (1976), pp. 652-3, 890.
	Eliasson, ed. <i>Carbohydrates in Food</i> , Chapter 4: "Cell Wall Polysaccharide: Structural, Chemical and Analytical Aspects," Marcel Dekker, Inc., New York, (1996) pp 191, 195.

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	